SEARCH

SEARCH BY CITATION

References

  • 1
    Lynch BA, Lambeng N, Nocka K, Kensel-Hammels P, Bajjalieh SM, Matagne AC, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Nat Acad Sci 2004; 101: 98616.
  • 2
    Zona C, Pieri M, Klitgaard H, Margineanu D-G. ucb 34714, a new pyrrolidone derivative, inhibits Na+ currents in rat cortical neurons in culture. Epilepsia 2004; 45(Suppl 7): 146.
  • 3
    Kenda BM, Matagne AC, Talaga PE, Pasau PM, Differding E, Lallemand BI, Frycia AM, Moureau FG, Klitgaard HV, Gillard MR, Fuks B, Michel P. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem 2004; 47: 53049.
  • 4
    Matagne A, Kenda B, Michel P, Klitgaard H. ucb 34714, a new pyrrolidone derivative, suppresses seizures epileptogenesis in animal models of chronic epilepsy in vivo. Epilepsia 2003; 44(Suppl 8): 534.
  • 5
    Lamberty Y, Ardid D, Eschalier A, Alloui A, Matagne A, Kenda B, Michel P, Klitgaard H. A new pyrrolidone derivative, ucb 34714, is effective in neuropathic pain models in rats: comparison with gabapentin. J Pain 2003; 4(Suppl 1): 53.
  • 6
    De Ryck M, Matagne A, Kenda B, Michel P, Klitgaard H. Contrasting effects of ucb 34714 and drugs for essential tremor on harmaline-induced elicited versus spontaneous tremor and sedation in rats. Mov Disord 2004; 19(Suppl 9): S443.
  • 7
    FDA Guidance for Industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers, 2005.
  • 8
    Cutler NL, Sramek JJ, Greenblatt DJ, Chaikin P, Collins J. Defining the maximum tolerated dose: an update. J Clin Pharmacol 2000; 40: 1183204.
  • 9
    Jasper HH. The ten-twenty electrode system of the International Federation. Electroencephalogr Clin Neurophysiol 1958; 10: 3715.
  • 10
    Parkin C, Kerr JS, Hindmarch I. The effects of practice on choice reaction time and critical flicker fusion threshold. Hum Psychopharmacol 1997; 12: 6570.
  • 11
    Griffiths AN, Marshall RW, Richens A. Saccadic eye movement analysis as a measure of drug effects on human psychomotor performance. Br J Clin Pharmacol 1984; 18: 73S82S.
  • 12
    Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1970; 12: 24558.
  • 13
    Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974; 47: 2118.
  • 14
    Gouch K, Hutchinson M, Keene O, Byron B, Ellis S, Lacey L, McKellar J. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint Working Party. Drug Inf J 1995; 29: 103948.
  • 15
    Smith BP, Vandenhende FR, Desarte KA, Farid NA, Welch PA, Callaghan JT, Forghe ST. Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000; 17: 127883.
  • 16
    Yin Y, Chen C. Trial design optimization for studying dose proportionality. Clin Pharmacol Ther 2000; 67: 159.
  • 17
    Yin Y, Chen C. Optimizing first-time-in-human trial design for studying dose proportionality. Drug Inf J 2001; 35: 106578.